NCT04883437 2026-02-09
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Emory University
Phase 2 Recruiting
Clinical Trials
5 trialsNCT02362035 2025-12-11
KEYNOTE145
Acerta Pharma BV
Phase 1/2 Completed
NCT02180711 2025-10-15
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Acerta Pharma BV
Phase 1/2 Active not recruiting
NCT04257578 2025-10-08
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
University of Washington
Phase 1/2 Active not recruiting
NCT04836832 2022-06-07
Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Withdrawn